Can we cure breast cancer
with adjuvant trastuzumab?
Review of its impact on costs
and benefits
Joseph Ragaz, MD, FRCPC

Harnessing evidence to
optimize cancer control
Ways the Canadian Strategy
for Cancer Control is helping
develop CPGs
George P. Browman, MD, MSc, FRCPC,
Louise Zitzelsberger, PhD and Anna Maria Boscaino

How to improve oncology
education in Canada
Changes needed in the early and
ongoing learning programs for
physicians who treat cancer patients
Henry R. Shibata, MD, MSc, FRCSC, FACS

Cover photo: LYMPHOMA CELLS, SEM. s.gshmeissner/spl/publiphoto

Essential reading: research
updates and commentaries
Review of important clinical trial data
originally presented at the 41ST Annual
Meeting of the American Society
Clinical Oncology
With commentaries by Sharlene Gill, MD, MPH, FRCPC
Debjani Grenier, MD, FRCPC, Hagen Kennecke, MD,
FRCPC and Ralph Wong, MD, FRCPC

Professional meetings roster
Your calendar dates for essential conferences and symposia

New drugs and indications
A review of recent cancer therapy
approvals in Canada and the U.S.